Use of Statins and the Risk of Parkinson's Disease: A Retrospective Case-Control Study in the UK

Authors: Becker, Claudia1; Jick, Susan S.2; Meier, Christoph R.

Source: Drug Safety, Volume 31, Number 5, 2008 , pp. 399-407(9)

Publisher: Adis International

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Background: Case reports have related the use of HMG-CoA reductase inhibitors (`statins') to Parkinson's disease (PD). Paradoxically, however, statins may have potentially beneficial effects on neurodegenerative diseases due to their anti-inflammatory properties.

Objective: To explore the risk of the development of PD in association with untreated hyperlipidaemia and with hyperlipidaemia treated with lipid-lowering drugs in the UK primary care setting.

Methods: We conducted a case-control analysis using the UK-based General Practice Research Database (GPRD). Cases were incident PD cases ≥40 years of age between 1994 and 2005. One control was matched to each PD case based on age, sex, general practice and index date. Lipid-lowering drug use was assessed by exposure timing (current vs past use) and by exposure duration (1-9, 10-29 or ≥30 prescriptions) prior to the index date for both cases and controls. Odds ratios (OR) were calculated using conditional logistic regression, adjusted for body mass index, smoking and various cardiovascular, metabolic and psychiatric co-morbidities.

Results: We identified 3637 cases with an incident idiopathic PD diagnosis, and the same number of controls. Compared with patients without hyperlipidaemia, those with untreated hyperlipidaemia did not have an altered relative PD risk (adjusted OR 0.98, 95% CI 0.74, 1.30). The adjusted ORs for current use of ≥30 prescriptions for statins or fibrates compared with non-use of statins or fibrates were 1.06 (95% CI 0.75, 1.51) and 1.25 (95% CI 0.51, 3.06), respectively.

Conclusions: In this observational study, the long-term use of statins or fibrates was not associated with a substantially altered relative risk of developing PD.

Keywords: HMG CoA reductase inhibitors; Parkinson's disease

Document Type: Research article

Affiliations: 1: 1 Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacology and Toxicology, University Hospital Basel, Basel, Switzerland 2: 2 Boston Collaborative Drug Surveillance Program, Boston University Medical Center, Lexington, Massachusetts, USA

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$54.95 plus tax

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A